GlassScriptPhysician profile
Kevin J Kurtz
NPI 1396711057
$2,442.03
in general payments reported to CMS, 2019-2025
30 companies · $180 in 2025
The $180 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $689 · 2020: $317 · 2021: $272 · 2022: $243 · 2023: $390 · 2024: $350 · 2025: $180.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $920.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $919.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $368.15 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $291.96 | 2019-2025 | Repatha, Otezla, Repatha |
| Glaxosmithkline, LLC. | $260.13 | 2019-2024 | Arexvy, Trelegy Ellipta, Shingrix |
| Sanofi-Aventis U.S. LLC | $186.97 | 2019-2021 | |
| Pfizer INC. | $184.72 | 2019-2023 | |
| Astellas Pharma US INC | $182.88 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $166.59 | 2019-2021 | |
| Lilly USA, LLC | $96.82 | 2019-2023 | Mounjaro, Emgality, Jardiance |
| Abbvie INC. | $70.11 | 2021-2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $64.30 | 2019 | |
| Exact Sciences Corporation | $63.70 | 2023-2025 | Cologuard Collection Kit |
| Axsome Therapeutics, INC. | $53.43 | 2024-2025 | Auvelity, Symbravo |
| Novartis Pharmaceuticals Corporation | $49.43 | 2019-2023 | |
| Viatris Specialty LLC | $49.17 | 2025 | Yupelri |
| Bayer Healthcare Pharmaceuticals INC. | $42.98 | 2022-2023 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $40.93 | 2019-2020 | |
| Irhythm Technologies, INC. | $36.03 | 2019-2020 | |
| Neurelis, INC. | $34.57 | 2023 | Valtoco |
| Otsuka America Pharmaceutical, INC. | $27.72 | 2024 | Rexulti |
| Takeda Pharmaceuticals U.S.A., INC. | $27.53 | 2021-2022 | |
| Sumitomo Pharma America, INC. | $17.50 | 2025 | Gemtesa |
| Idorsia Pharmaceuticals US INC | $16.89 | 2023 | Quviviq |
| Valeritas, INC. | $16.32 | 2019 | |
| Phathom Pharmaceuticals, INC. | $16.31 | 2024 | Voquezna |
| Mylan Specialty L.P. | $15.05 | 2023 | Yupelri |
| Allergan, INC. | $13.17 | 2020 | |
| Abbott Laboratories | $12.87 | 2021 | |
| Merck Sharp & Dohme LLC | $12.23 | 2019 | |
| Medicure Pharma INC. | $12.23 | 2022 | |
| Amarin Pharma, INC. | $11.34 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kevin Kurtz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.